Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE GSK and Takeda to Provide "Boxed" Warning on Avandia and Actos
August 27, 2007
-
ARCHIVE UK High Court Orders NICE to Amend Guidance for Alzheimer's Disease
August 27, 2007
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
August 20, 2007
-
ARCHIVE Fixed-Point ADR Observation Project to Be Expanded: New SD Director
August 20, 2007
-
ARCHIVE Bayer Yakuhin to Focus on Specialty Drugs
August 20, 2007
-
ARCHIVE Summary of FPMAJ's Opinions on NHI Drug Pricing System
August 20, 2007
-
ARCHIVE Bayer Launches l'strogel without NHI Price Listing
August 20, 2007
-
ARCHIVE Number of Essential GCP Documents to Be Halved
August 20, 2007
-
ARCHIVE Takeda to License CCR5 Antagonists to Tobira Therapeutics
August 20, 2007
-
ARCHIVE Takeda, Santhera Extend Marketing Collaboration in EU for SNT-MC17
August 20, 2007
-
ARCHIVE Astellas Reorganizes European Business Functions
August 20, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF(1)
August 20, 2007
-
ARCHIVE Chugai: Half-Year Sales Up 12%, Ordinary Profits Up 30.5%
August 20, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF(2)
August 20, 2007
-
ARCHIVE Takeda, Taiyo in Dispute over Recall of Pansporin
August 20, 2007
-
ARCHIVE Nippon Shinyaku to Create "Monitor System" to Have New Compounds Assessed by Outside Experts
August 20, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
August 20, 2007
-
ARCHIVE WC6 on Alternatives and Animal Use in Life Sciences to Be Held in Tokyo
August 20, 2007
-
ARCHIVE TOPICS/ACTOS Offers Safety Profile: Takeda
August 20, 2007
-
ARCHIVE R&D NEWS IN BRIEF
August 20, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…